{"id":"das181-covid-19","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAS181 consists of the extracellular domain of human ACE2 fused to the Fc region of human IgG1, functioning as a decoy receptor. It binds to the spike protein of SARS-CoV-2, preventing the virus from attaching to and infecting host cells. This mechanism aims to reduce viral load and disease severity in COVID-19 patients.","oneSentence":"DAS181 is a recombinant fusion protein that blocks SARS-CoV-2 entry into human cells by targeting the ACE2 receptor on the cell surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:35.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (moderate to severe disease)"}]},"trialDetails":[{"nctId":"NCT03808922","phase":"PHASE3","title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","status":"RECRUITING","sponsor":"Ansun Biopharma, Inc.","startDate":"2019-05-23","conditions":"Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised","enrollment":274},{"nctId":"NCT04354389","phase":"PHASE2, PHASE3","title":"DAS181 for STOP COVID-19","status":"WITHDRAWN","sponsor":"Ansun Biopharma, Inc.","startDate":"2020-07-25","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04298060","phase":"PHASE2","title":"DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","status":"UNKNOWN","sponsor":"Ansun Biopharma, Inc.","startDate":"2020-07","conditions":"Influenza Infection, SAD-RV Infection and COVID-19","enrollment":280},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04324489","phase":"NA","title":"DAS181 for Severe COVID-19: Compassionate Use","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2020-03-06","conditions":"COVID-19","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DAS181 COVID-19","genericName":"DAS181 COVID-19","companyName":"Ansun Biopharma, Inc.","companyId":"ansun-biopharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAS181 is a recombinant fusion protein that blocks SARS-CoV-2 entry into human cells by targeting the ACE2 receptor on the cell surface. Used for COVID-19 (moderate to severe disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}